Receptor Tyrosine Kinase Treatment Market Size & Share, by Product Type (Epidermal Growth Factor Receptor [EGFR] Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor [VEGFR] Tyrosine Kinase Inhibitors); Application (Lung Cancer, Breast Cancer, Renal Cell Cancer); Distribution (Hospital Pharmacies, Independent Pharmacies, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 3626
  • Published Date: Feb 16, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023-2035

Receptor Tyrosine Kinase Treatment Market size is poised to cross USD 110 Billion by the end of 2035, growing at a CAGR of 8% during the forecast period, i.e., 2023-2035. In the year 2022, the industry size of receptor tyrosine kinase treatment was over USD 57 Billion. The growth of the market can be attributed by growing cases of cancer all around the world. According to the World Health Organization, nearly 10 million deaths, or nearly one in six deaths, were caused by cancer in 2020, making it the top cause of death globally. Hence the demand for targeted therapies are growing. Targeted therapy includes tyrosine kinase inhibitors (TKIs). A targeted therapy lessens the harm done to healthy cells by locating and attacking particular cancer cell types. Hence, the adoption of TKIs is growing extensively. Further, among this the receptor tyrosine kinase treatment is popular. Cell growth and survival are two important processes that are regulated by receptor tyrosine kinase (RTK) activity. But it has been demonstrated that dysregulation of RTK correlates with the onset and spread of many malignancies, and it has been discovered in a variety of tumors. As a result, RTK has gained popularity as a therapeutic target.

Additionally, there has been growing initiatives taken to spread awareness regarding the diagnosis and availability of cancer treatment. Also, governments are initiating their efforts and making healthcare facilities accessible to people. Further, since there has been growing prevalence of cancer, the R&D activities are also on boost. Moreover, the market for receptor tyrosine kinase treatment is being driven by the existence of patient support programmes. A lot of public and private organizations are concentrating on offering monetary and medical support for the therapy of numerous cancer symptoms. As a result, a large number of patients are receiving the necessary care, which is growing the patient base. These initiatives aid patients in sticking to their treatment plans.


Receptor-Tyrosine-Kinase-Treatment-Market
Get more information on this report: Request Free Sample PDF

Receptor Tyrosine Kinase Treatment Sector: Growth Drivers and Challenges

Growth Drivers

  • Surge in Prevalence of Obesity - Over 1 billion individuals, including 650 million adults, 340 million teenagers, and 39 million children, are obese worldwide. This figure is still rising. According to the WHO, 167 million adults and children would have worse health by 2025 as a result of being overweight or obese. Obesity and overweight could alter the body in ways that contribute to the development of cancer. Long-lasting inflammation, elevated levels of insulin, insulin-like growth factor, and sex hormones are a few instances of these changes. The more additional weight a person puts on and the longer they are overweight, the higher their risk of developing cancer is. For instance, obesity and being overweight are associated with a greater risk of 13 different types of cancer.
  • Growing Investment in Healthcare - The predicted cost of healthcare in India in 2020 was about 190 billion US dollars and this amount is estimated rise to about 370 billion US dollars.
  • Clinical Approval of Kinase Inhibitors - Up until September 2021, the FDA approved about 72 small molecule kinase inhibitor medicines, and other regulatory bodies also approved more inhibitors throughout that time.
  • Upsurge in Investment by Pharmaceutical Companies on R&D- Globally, the pharmaceutical sector invested over 230 billion dollars on research and development in 2021.
  • Rising Preference for Oral Drugs - Approximately 59% of established small-molecule medicinal compounds that are commercially accessible are given orally.

Challenges

  • High cost of tyrosine kinases therapies - A lack of qualified personnel who are unable to give patients the treatment they need is limiting the growth of the receptor tyrosine kinase treatment market on a global scale. Market expansion in the R&D sector is significantly constrained by higher expenditures and challenging regulatory approval processes. Additionally, a corollary of the high development costs of medications is a higher market price for the drug following approval. The National Cancer Institute estimates that the average cost of medical care and medications after a cancer diagnosis would be more than USD 40,000 in 2022. The high expense of the treatment has thus up until a certain point limited market penetration.
  • Lack of funds for R&D activities
  • Challenges faced by clinical trials for commercialization of tyrosine kinase inhibitors

Receptor Tyrosine Kinase Treatment Market: Key Insights

Base Year

2022

Forecast Year

2023-2035

CAGR

8%

Base Year Market Size (2022)

USD 57 Billion

Forecast Year Market Size (2035)

USD 110 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Receptor Tyrosine Kinase Treatment Segmentation

The global receptor tyrosine kinase treatment market is segmented and analyzed for demand and supply by application into lung cancer, breast cancer, renal cell cancer, and others. Out of which the breast cancer segment is anticipate to hold the largest market share over the forecast period. The growth of the segment can be attributed to growing cases of breast cancer all across the world. Breast cancer is the second most common type of cancer and the most common in females, with about 20% of all cases to be HER-2 positive. As a result, numerous HER2-targeted treatments have been introduced lately, including the TKIs lapatinib, neratinib, tucatinib, and pyrotinib. However, TKIs have proven to be successful in this situation where the outlook is still grim and there are few other therapy choices.

The global receptor tyrosine kinase treatment market is also segmented and analyzed for demand and supply by product type into epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors, platelet-derived growth factor receptor (PDGFR) tyrosine kinase inhibitors, and others. Amongst these segments, the vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors segment is anticipated to grow at the highest rate over the forecast period. This growth of the segment can be attributed to rising cases of lung cancer all across the world. Hence the demand for this treatment is estimated to increase has it has been observed to be one of the efficient treatment for lung cancer. Further, it is also used for treatment for various other cancers which includes, breast cancer, cervical cancer and more.

Our in-depth analysis of the global receptor tyrosine kinase treatment market includes the following segments:

                 By Product Type

  • Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
  • Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors
  • Platelet-Derived Growth Factor Receptor (PDGFR) Tyrosine Kinase Inhibitors
  • Others

              By Application

  • Lung Cancer
  • Breast Cancer
  • Renal Cell Cancer
  • Others

            By Distribution Channel

  • Hospital Pharmacies
  • Independent Pharmacies
  • Online Pharmacies

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Receptor Tyrosine Kinase Treatment Industry - Regional Synopsis

North America Market Forecast

The North American receptor tyrosine kinase treatment market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2035, backed by high prevalence of cancer in the region, increasing R&D activities with tyrosine kinase inhibitors, and the presence of prominent market players, with the U.S. dominating over the region. In 2020, approximately 1.8 million new cases of cancer were diagnosed in the U.S. with a mortality rate higher among men than women. Additionally, there has been growing investment on R&D in order to develop novel cancer treatment in this region. Hence, this factor is also anticipated to boost the market growth in this region.

Asia-Pacific Market Forecast

Moreover, Asia-Pacific region is expected to witness the fastest market growth owing to the boost in prevalence of cancer all across this region. Between 2012 and 2018, the number of newly diagnosed cancer cases in Asia-Pacific rose from about 5 million to approximately 8 million. The region's population is ageing at a record-breaking rate, which is a major factor in this development. Hence, there has been rise in research and development activities for cancer and related diseases in this region, which is expected to boost the market further. Moreover, increased use of kinase inhibitors for newer applications in emerging economies such as China and India would provide new opportunities for market players to invest in the region, further boosting the market growth.

Research Nester
Global-Receptor-Tyrosine-Kinase-Treatment-Market-size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Receptor Tyrosine Kinase Treatment Landscape

top-features-companies
    • Bristol-Myers Squibb Company
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis 
    • Boehringer Ingelheim GmbH
    • Eton Bioscience, Inc.
    • GlaxoSmithKline plc
    • Merck KGaA
    • AstraZeneca
    • Novartis AG
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd.
    • Johnson & Johnson Services, Inc.

In the News

  • A study conducted provided information on the potential cardiotoxicity of a list of FDA approved Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors and ranked them by their potential cardiotoxic risk associated in patients with solid tumors.

  • A research investigated the efficacy of EGFR-TKIs in older patients, where patients of 65 years or older with EGFR-mutated Stage IIIB–IV non-small-cell lung cancer (NSCLC) were enrolled and the efficacy and prognosis of first-line EGFR-TKI treatment was evaluated. EGFR-TKIs are standard first-line treatments for advanced EGFR-mutated non-small-cell lung cancer (NSCLC) patients.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 3626
  • Published Date: Feb 16, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The major factors driving the growth of the market are surge in prevalence of obesity, growing investment in healthcare, clinical approval of kinase inhibitors, and others.

The market is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2023-2035.

High cost of tyrosine kinase therapies, lack of funds for R&D activities, and challenges faced by clinical trials for commercialization of tyrosine kinase inhibitors are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Eton Bioscience, Inc., GlaxoSmithKline plc, and more.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by product type, application, distribution channel and by region.

The breast cancer segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Receptor Tyrosine Kinase Treatment Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying